THE PREVALENCE OF CANCER AND ITS RELATION TO DISEASE ACTIVITY IN PATIENTS WITH ACROMEGALY : TWO CENTERS' EXPERIENCE
Copyright © 2020 AACE. Published by Elsevier Inc. All rights reserved..
OBJECTIVE: Acromegaly is characterized by increased serum concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although animal studies have demonstrated a relationship between these hormones and cancer risk, the results of human studies evaluating cancer prevalence in acromegaly are inconsistent. We aimed to investigate the prevalence of malignant neoplasms in patients with acromegaly.
METHODS: Cancer risk was evaluated in a cohort of 280 patients (male/female: 120/160; mean age: 50.93 ± 12.07 years) with acromegaly. Patients were categorized into 2 groups according to the presence or absence of cancer. Standard incidence ratios were calculated as compared to the general population.
RESULTS: From 280 patients, cancer was diagnosed in 19 (6.8%) patients; 9 (47%) of them had thyroid cancer, which was the most common cancer type. Standard incidence ratios of all cancers were 0.8 (95% CI, 0.5-1.1) and 1.0 (95% CI, 0.8-1.3) in men and women, respectively. Compared to patients without cancer, the current age was higher in patients with cancer (59 [49-65] to 51 [42-59], P = .027). In contrast, the age at diagnosis was similar in both groups. Not only was the time to diagnosis and disease duration similar in both groups but also the basal and current GH and IGF-1 levels. The prevalence of active disease was also similar between the groups (32% to 23%, P = .394).
CONCLUSION: Our findings were not consistent with the studies suggesting that patients with acromegaly encounter an increased cancer risk. Furthermore, there were similar basal and current GH and IGF-1 levels in patients with acromegaly, both with and without cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 27(2021), 1 vom: 21. Jan., Seite 51-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ucan, Bekir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12629-01-5 |
|---|
| Anmerkungen: |
Date Completed 25.01.2021 Date Revised 25.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4158/EP-2020-0398 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320378306 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320378306 | ||
| 003 | DE-627 | ||
| 005 | 20231225173438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4158/EP-2020-0398 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320378306 | ||
| 035 | |a (NLM)33475501 | ||
| 035 | |a (PII)S1530-891X(20)48323-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ucan, Bekir |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a THE PREVALENCE OF CANCER AND ITS RELATION TO DISEASE ACTIVITY IN PATIENTS WITH ACROMEGALY |b TWO CENTERS' EXPERIENCE |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2021 | ||
| 500 | |a Date Revised 25.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 AACE. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: Acromegaly is characterized by increased serum concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although animal studies have demonstrated a relationship between these hormones and cancer risk, the results of human studies evaluating cancer prevalence in acromegaly are inconsistent. We aimed to investigate the prevalence of malignant neoplasms in patients with acromegaly | ||
| 520 | |a METHODS: Cancer risk was evaluated in a cohort of 280 patients (male/female: 120/160; mean age: 50.93 ± 12.07 years) with acromegaly. Patients were categorized into 2 groups according to the presence or absence of cancer. Standard incidence ratios were calculated as compared to the general population | ||
| 520 | |a RESULTS: From 280 patients, cancer was diagnosed in 19 (6.8%) patients; 9 (47%) of them had thyroid cancer, which was the most common cancer type. Standard incidence ratios of all cancers were 0.8 (95% CI, 0.5-1.1) and 1.0 (95% CI, 0.8-1.3) in men and women, respectively. Compared to patients without cancer, the current age was higher in patients with cancer (59 [49-65] to 51 [42-59], P = .027). In contrast, the age at diagnosis was similar in both groups. Not only was the time to diagnosis and disease duration similar in both groups but also the basal and current GH and IGF-1 levels. The prevalence of active disease was also similar between the groups (32% to 23%, P = .394) | ||
| 520 | |a CONCLUSION: Our findings were not consistent with the studies suggesting that patients with acromegaly encounter an increased cancer risk. Furthermore, there were similar basal and current GH and IGF-1 levels in patients with acromegaly, both with and without cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acromegaly | |
| 650 | 4 | |a cancer risk | |
| 650 | 4 | |a disease activity | |
| 650 | 7 | |a Human Growth Hormone |2 NLM | |
| 650 | 7 | |a 12629-01-5 |2 NLM | |
| 650 | 7 | |a Insulin-Like Growth Factor I |2 NLM | |
| 650 | 7 | |a 67763-96-6 |2 NLM | |
| 650 | 7 | |a Growth Hormone |2 NLM | |
| 650 | 7 | |a 9002-72-6 |2 NLM | |
| 700 | 1 | |a Kizilgul, Muhammed |e verfasserin |4 aut | |
| 700 | 1 | |a Karci, Alper Cagri |e verfasserin |4 aut | |
| 700 | 1 | |a Duger, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Erkam Sencar, Muhammed |e verfasserin |4 aut | |
| 700 | 1 | |a Imga, Narin Nasiroglu |e verfasserin |4 aut | |
| 700 | 1 | |a Demirci, Taner |e verfasserin |4 aut | |
| 700 | 1 | |a Berker, Dilek |e verfasserin |4 aut | |
| 700 | 1 | |a Erman Cakal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists |d 1995 |g 27(2021), 1 vom: 21. Jan., Seite 51-55 |w (DE-627)NLM095479376 |x 1530-891X |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:1 |g day:21 |g month:01 |g pages:51-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4158/EP-2020-0398 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 1 |b 21 |c 01 |h 51-55 | ||